{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:39:02Z","timestamp":1792931942506,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005968","name":"Leukemia Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (<jats:italic>n<\/jats:italic>\u2009=\u2009309). t-CC had a distinct genetic and cytogenetic profile: pathogenic variants (PV) in <jats:italic>TET2<\/jats:italic> and <jats:italic>SRSF2<\/jats:italic> were enriched in t-CC, whereas <jats:italic>TP53<\/jats:italic> PV was more common in t-MN. Ten (30%) t-CC patients developed a subsequent t-MN, with a cumulative incidence of 13%, 23%, and 50% at 6 months, 1, and 5 years, respectively. At t-MN progression, 44% of evaluable patients had identifiable clonal evolution. The median survival following t-CC was significantly superior compared all t-MN phenotype including t-MDS with &lt;5% bone marrow blasts (124.5 vs. 16.3 months, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) respectively. The presence of cytogenetic abnormality and the absence of variants in <jats:italic>DNMT3A<\/jats:italic>, <jats:italic>TET2<\/jats:italic>, or <jats:italic>ASXL1<\/jats:italic> (<jats:italic>DTA<\/jats:italic>-genes) were associated with a higher likelihood of developing a subsequent t-MN and an inferior survival. We describe a putative precursor entity of t-MN with distinct features and outcomes.<\/jats:p>","DOI":"10.1038\/s41408-022-00703-8","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T14:03:45Z","timestamp":1657289025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun Vinod","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-8404","authenticated-orcid":false,"given":"Hassan B.","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5247-5065","authenticated-orcid":false,"given":"Ahmad","family":"Nanaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-2619","authenticated-orcid":false,"given":"Kristen","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-8163","authenticated-orcid":false,"given":"Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"703_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1200\/EDBK_239083","volume":"39","author":"AE DeZern","year":"2019","unstructured":"DeZern AE, Malcovati L, Ebert BL. CHIP, CCUS, and other acronyms: definition, implications, and impact on practice. Am Soc Clin Oncol Educ Book. 2019;39:400\u201310.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"703_CR2","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","volume":"126","author":"B Kwok","year":"2015","unstructured":"Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126:2355\u201361.","journal-title":"Blood."},{"key":"703_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","volume":"17","author":"ME McNerney","year":"2017","unstructured":"McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17:513.","journal-title":"Nat Rev Cancer"},{"key":"703_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00454-y","volume":"11","author":"K Nadiminti","year":"2021","unstructured":"Nadiminti K, Sidiqi MH, Meleveedu K, Alkhateeb HB, Hogan WJ, Litzow M, et al. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2021;11:63.","journal-title":"Blood Cancer J"},{"key":"703_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","volume":"35","author":"CJ Gibson","year":"2017","unstructured":"Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35:1598\u2013605.","journal-title":"J Clin Oncol"},{"key":"703_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","volume":"21","author":"CC Coombs","year":"2017","unstructured":"Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21:374\u201382.e4.","journal-title":"Cell Stem Cell"},{"key":"703_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-16805-5","volume":"11","author":"TH Mouhieddine","year":"2020","unstructured":"Mouhieddine TH, Sperling AS, Redd R, Park J, Leventhal M, Gibson CJ, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020;11:1\u20139.","journal-title":"Nat Commun"},{"key":"703_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52:1219\u201326.","journal-title":"Nat Genet"},{"key":"703_CR9","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1182\/bloodadvances.2020003976","volume":"5","author":"M Li","year":"2021","unstructured":"Li M, Binder M, Lasho T, Ferrer A, Gangat N, Al-Kali A, et al. Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Adv. 2021;5:2272\u20138.","journal-title":"Blood Adv"},{"key":"703_CR10","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","volume":"129","author":"L Malcovati","year":"2017","unstructured":"Malcovati L, Gall\u00ec A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129:3371\u20138.","journal-title":"Blood."},{"key":"703_CR11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1182\/blood.2021011323","volume":"138","author":"A Gall\u00ec","year":"2021","unstructured":"Gall\u00ec A, Todisco G, Catamo E, Sala C, Elena C, Pozzi S, et al. Relationship between clone metrics and clinical outcome in clonal cytopenia. Blood. 2021;138:965\u201376.","journal-title":"Blood."},{"key":"703_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/modpathol.2016.67","volume":"29","author":"RS Goswami","year":"2016","unstructured":"Goswami RS, Wang SA, DiNardo C, Tang Z, Li Y, Zuo W, et al. Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. Mod Pathol. 2016;29:727\u201334.","journal-title":"Mod Pathol"},{"key":"703_CR13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood."},{"key":"703_CR14","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola M. Myelodysplastic syndromes. N. Engl J Med. 2020;383:1358\u201374.","journal-title":"N. Engl J Med"},{"key":"703_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40291-021-00540-8","volume":"25","author":"N Mehta","year":"2021","unstructured":"Mehta N, He R, Viswanatha DS. Internal standardization of the interpretation and reporting of sequence variants in hematologic neoplasms. Mol Diagnosis Ther. 2021;25:517\u201326.","journal-title":"Mol Diagnosis Ther"},{"key":"703_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"703_CR17","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1\u2013pl.","journal-title":"Sci Signal"},{"key":"703_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"703_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl J Med. 2017;377:111\u201321.","journal-title":"N. Engl J Med"},{"key":"703_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/genes11070749","volume":"11","author":"A Higgins","year":"2020","unstructured":"Higgins A, Shah MV. Genetic and genomic landscape of secondary and therapy-related acute myeloid leukemia. Genes 2020;11:749.","journal-title":"Genes"},{"key":"703_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","volume":"5","author":"LM Morton","year":"2019","unstructured":"Morton LM, Dores GM, Schonfeld SJ, Linet MS, Sigel BS, Lam CJK, et al. Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA Oncol. 2019;5:318\u201325.","journal-title":"JAMA Oncol"},{"key":"703_CR22","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","volume":"23","author":"JI Hsu","year":"2018","unstructured":"Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell. 2018;23:700\u201313.e6.","journal-title":"Cell Stem Cell"},{"key":"703_CR23","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood.2020009195","volume":"138","author":"MK Imgruet","year":"2021","unstructured":"Imgruet MK, Lutze J, An N, Hu B, Khan S, Kurkewich J, et al. Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. Blood. 2021;138:790\u2013805.","journal-title":"Blood."},{"key":"703_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/aje\/kwn120","volume":"168","author":"SW Duffy","year":"2008","unstructured":"Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol. 2008;168:98\u2013104.","journal-title":"Am J Epidemiol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00703-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00703-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00703-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:09:57Z","timestamp":1669234197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00703-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00703-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patnaik\u2014Membership on an entity\u2019s Board of Directors or advisory committees (Stemline Therapeutics) and Research funding (Kura Oncology). Al-Kali\u2014Research funding (Novartis), and Research support to institution (Astex). Litzow\u2014Research funding (AbbVie, Astellas, Amgen, Actinium, Pluristem); Advisory board (Jaz, Omeros); Data monitoring committee (BioSight). All other authors disclose no conflicts.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}